Recent extremely meaningful positive changes in fundamentals have benefitted Halozyme Therapeutics Inc (NASDAQ: HALO): the consensus estimate for December, 2024 increased significantly, the stock’s power rating rose above 70, the consensus estimate for December, 2025 increased significantly, and significant quarterly earnings acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of A. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, HALO is expected to continue to be a major Value Builder.
Halozyme Therapeutics has a current Value Trend Rating of A (Highest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Halozyme Therapeutics has a very high Power Rating of 85 and a very high Appreciation Score of 99, triggering the Highest Value Trend Rating.
Recent Price Action
On 7/5/24, Halozyme Therapeutics Inc (NASDAQ: HALO) stock declined slightly by -0.9%, closing at $51.56. However, this decline was accompanied by unusually low trading volume at 58% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -0.8% during the last week.
Be the first to comment